ANGIOTENSIN-CONVERTING ENZYME INHIBITORS: A CHOICE OF THE DRUG IN CLINICAL PRACTICE GIVEN THE EFFECTIVENESS AND SAFETY OF USE

Cover Page

Cite item

Full Text

Abstract

Aim. To provide data on main clinical and pharmacological parameters of angiotensin converting enzyme inhibitors (ACE inhibitors). Materials and methods. A review of national and foreign publications in the main search engines (PubMed, eLibrary, etc.) for the period 2000-2019 was conducted. Results. Prevention and effective treatment of cardiovascular diseases are a priority area of modern cardiology. Cardiovascular disease remains the leading cause of death worldwide. Arterial hypertension (AH) occupies the leading position among cardiovascular diseases, it is characterized by a severe progressive course, leads to other cardiovascular disorders, including chronic heart failure and chronic kidney disease, and also causes difficulties in the selection of therapy. The review presents data on the mechanism of action and clinical and pharmacological properties of ACE inhibitors, the main class of antihypertensive drugs, that affect the main link of pathogenesis of hypertension and cardiovascular complications, the renin-angiotensin-aldosterone system. This group of drugs has demonstrated a high efficacy at different stages of cardiovascular pathology in numerous clinical studies. The article presents a brief description of third-generation ACE inhibitor fosinopril, as well as the results of foreign and national studies proving its effectiveness and safety in patients with hypertension, chronic heart failure and chronic kidney disease with concomitant diabetes mellitus. The main difference between fosinopril and other ACE inhibitors is the dual route of elimination. This allows us to recommend the drug to patients with liver and kidneys disorders, as well as to elderly people without adjusting the dosage regimen and monitoring pharmacotherapy.

About the authors

Olga A. Mubarakshina

Burdenko Voronezh State Medical University

Email: mubarakshina@mail.ru
канд. мед. наук, доц. каф. клинической фармакологии Воронеж, Россия

Svetlana S. Liubavskaia

Burdenko Voronezh State Medical University

канд. мед. наук, доц. каф. клинической фармакологии Воронеж, Россия

Marina N. Somova

Burdenko Voronezh State Medical University

канд. мед. наук, доц. каф. клинической фармакологии Воронеж, Россия

Galina A. Batishcheva

Burdenko Voronezh State Medical University

д-р мед. наук, проф., зав. каф. клинической фармакологии Воронеж, Россия

References

  1. Демографический ежегодник России. 2013. http://www.gks.ru/bgd/regl/B15_16/Main.htm @@Demograficheskii ezhegodnik Rossii. 2013. http://www.gks.ru/bgd/regl/B15_16/Main.htm (in Russian).
  2. Heidenreich PA, Trogdon JG, Khavjou OA et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123 (8): 933-44.
  3. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.
  4. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16 (1): 6-31. @@Chazova I.E., Zhernakova Yu.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019; 16 (1): 6-31 (in Russian).
  5. Толордова Г.А., Аринина Е.Е., Куликов А.Ю. Фармакоэкономический анализ лекарственного средства фозиноприл у больных с артериальной гипертензией. Фармакоэкономика. Теория и практика. 2016; 1: 70-8. @@ Tolordova G.A., Arinina E.E., Kulikov A.Iu. Farmakoekonomicheskii analiz lekarstvennogo sred-stva fozinopril u bol'nykh s arterial'noi gipertenziei. Farmakoekonomika. Teoriia i praktika. 2016; 1: 70-8 (in Russian).
  6. Fonarow GC, Stough WG, Abraham WT et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50 (8): 768-77.
  7. Гороховская Г.Н., Скотников А.С., Юн В.Л. Коморбидный больной артериальной гипертензией, хронической сердечной недостаточностью и хронической болезнью почек: роль фозиноприла. Мед. совет. 2018; 5: 15-9. @@Gorokhovskaia G.N., Skotnikov A.S., Iun V.L. Komorbidnyi bol'noi arterial'noi gipertenziei, khronic-heskoi serdechnoi nedostatochnost'iu i khronicheskoi bolezn'iu pochek: rol' fozinoprila. Med. so-vet. 2018; 5: 15-9 (in Russian).
  8. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34: 957-62.
  9. Smith GL, Lichtman JH, Bracken MB et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol 2016; 47: 987-96. ИНФОРМАЦИЯ ОБ АВТОРАХ / INFORMATION ABOUT THE AUTHORS
  10. Остроумова О.Д., Максимов М.Л. Место ингибиторов ангиотензин-превращающего фермента в лечении артериальной гипертонии у различных групп пациентов. Кардиоваскулярная терапия и профилактика. 2010; 7: 90-6. @@ Ostroumova O.D., Maksimov M.L. Mesto ingibitorov angiotenzin-prevrashchaiushchego fermenta v lechenii arterial'noi gipertonii u razlichnykh grupp patsientov. Kardiovaskuliarnaia terapiia i profi-laktika. 2010; 7: 90-6 (in Russian).
  11. ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Hypertens 2013; 31 (7): 1281-357.
  12. Brunstrom M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med 2018; 178: 28-36.
  13. Ettehad D, Emdin CA, Ki ran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957-67.
  14. Агабабян И.Р., Тошназаров Ш.М., Сафарова Ф.Ф. и др. Эффективность комбинированного применения ингибиторов АПФ в лечении хронической сердечной недостаточности. Вопросы науки и образования. 2019; 6 (52): 59-61. @@Agababian I.R., Toshnazarov Sh.M., Safarova F.F. i dr. Effekti vnost' kombinirovannogo primeneni-ia ingibitorov APF v lechenii khronicheskoi serdechnoi nedostatochnosti. Voprosy nauki i obrazo-vaniia. 2019; 6 (52): 59-61 (in Russian).
  15. Wenzel UO, Bode M, Kohl J et al. A pathogenic role of complement in arterial hypertension and hypertensive end organ damage. Am J Physiol Heart Circ Physiol 2017; 312 (3): H349-H354.
  16. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 7 (3): 5-26. @@Diagnostika i lechenie arterial'noi gipertenzii. Rossiiskie rekomendatsii (chetvertyi peresmotr). Systemic Hypertension. 2010; 7 (3): 5-26. (in Russian).
  17. Верткин А.Л. Фозиноприл - ингибитор АПФ с особыми свойствами. РМЖ. Кардиология. 2013; 36: 1831-5. @@Vertkin A.L. Fozinopril - ingibitor APF s osobymi svoistvami. RMZh. Kardiologiia. 2013; 36: 18315 (in Russian).
  18. Стрюк Р.И. Эффективность и безопасность фозиноприла в клинической практике. Consilium Medicum. 2015; 17 (1): 18-21. @@Stryuk R.I. Efficacy and safety in clinical practice fosinopril. Consilium Medicum. 2015; 17 (1): 1821. (in Russian).
  19. Государственный реестр лекарственных средств. http://grls.rosminzdrav.ru/grls.aspx @@Gosudarstvennyi reestr lekarstvennykh sredstv. http://grls.rosminzdrav.ru/grls.aspx (in Russian).
  20. Отрохова Е.В. Фозиноприл в лечении и профилактике хронической сердечной недостаточности у больных артериальной гипертензией: проблема оптимального выбора ингибитора ангиотензинпревращающего фермента. Фарматека. 2006; 20: 28-32. @@Otrokhova E.V. Fozinopril v lechenii i profilaktike khronicheskoi serdechnoi nedostatochnosti u bol'nykh arterial'noi gipertenziei: problema optimal'nogo vybora ingibitora angiotenzinprevrashcha-iushchego fermenta. Farmateka. 2006; 20: 28-32 (in Russian).
  21. Geluk CA, Asselbergs FW, Hillege HL et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. Eur Heart J 2005; 26 (13): 1314-20.
  22. Wald DS, Law M, Morris JK et al. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11000 Participants from 42 Trials. Am J Med 2009; 122: 290-300.
  23. Болезни сердца: руководство для врачей. Под ред. Р.Г.Органова, И.Г.Фоминой. М.: Литте-ра, 2006. @@Heart disease: a guide for doctors. Ed. R.G.Organova, I.G. Fomina. Moscow: Littera, 2006. (in Russian).
  24. Барышникова Г.А. Роль фозиноприла в лечении и профилактике сердечно-сосудистых заболеваний. Мед. совет. 2015; 12: 28-33. @@Baryshnikova G.A. Rol' fozinoprila v lechenii i profilaktike serdechno-sosudistykh zabolevanii. Med. sovet. 2015; 12: 28-33 (in Russian).
  25. Терещенко С.Н., Жиров И.В. Место ингибиторов ангиотензинпревращающего фермента в лечении кардиоренального синдрома. Эффективная фармакотерапия. 2011; 12: 28-33. @@Tereshchenko S.N., Zhirov I.V. Mesto ingibitorov angiotenzinprevrashchaiushchego fermenta v lechenii kardiorenal'nogo sindroma. Effektivnaia farmakoterapiia. 2011; 12: 28-33 (in Russian).
  26. Zhou KL, Pan DQ, Lou YY et al. Intermolecular interaction of fosinopril with bovine serum albumin (BSA): The multi-spectroscopic and computational investigation. J Mol Recognit 2018; 31 (8): e2716.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies